Last reviewed · How we verify
E coli vaccine 1 Dose A (e-coli-vaccine-1-dose-a)
At a glance
| Generic name | e-coli-vaccine-1-dose-a |
|---|---|
| Sponsor | Pfizer Inc. |
| Modality | Vaccine |
| Phase | Phase 1 |
Approved indications
Common side effects
- Blood Pressure Diastolic Decreased
- Heart Rate Decreased
- Tooth Pain
- Absolute Neutrophil Count Decreased
- Heart Rate Increased
- Headache
- Narcolepsy
- Runny Nose
- Dermatitis
- Abdominal discomfort
- Diarrhea
- Malaise
Key clinical trials
- Shigella CVD 31000: Study of Responses With Shigella-ETEC Vaccine Strain CVD 1208S-122 (PHASE1)
- A Study to Learn About a Vaccine Against E Coli in Healthy Adults (PHASE1)
- Immunogenicity Study of the Recombinant Human Papillomavirus Virus Type 6/11 Bivalent Vaccine (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- E coli vaccine 1 Dose A CI brief — competitive landscape report
- E coli vaccine 1 Dose A updates RSS · CI watch RSS
- Pfizer Inc. portfolio CI